DOP2011000288A - Fusiones y conjugados de farmaco - Google Patents

Fusiones y conjugados de farmaco

Info

Publication number
DOP2011000288A
DOP2011000288A DO2011000288A DO2011000288A DOP2011000288A DO P2011000288 A DOP2011000288 A DO P2011000288A DO 2011000288 A DO2011000288 A DO 2011000288A DO 2011000288 A DO2011000288 A DO 2011000288A DO P2011000288 A DOP2011000288 A DO P2011000288A
Authority
DO
Dominican Republic
Prior art keywords
farmaco
fusions
conjugates
farmaco fusions
Prior art date
Application number
DO2011000288A
Other languages
English (en)
Inventor
Christopher Herring
Lucy J Holt
Laurent S Jespers
Sebastian Mayer
Malgorzata Pupecka
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42308293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2011000288(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DOP2011000288A publication Critical patent/DOP2011000288A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DO2011000288A 2009-03-27 2011-09-20 Fusiones y conjugados de farmaco DOP2011000288A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16391709P 2009-03-27 2009-03-27

Publications (1)

Publication Number Publication Date
DOP2011000288A true DOP2011000288A (es) 2012-01-15

Family

ID=42308293

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2011000288A DOP2011000288A (es) 2009-03-27 2011-09-20 Fusiones y conjugados de farmaco

Country Status (24)

Country Link
US (2) US8779103B2 (es)
EP (1) EP2411054A2 (es)
JP (1) JP2012521971A (es)
KR (1) KR20110137819A (es)
CN (2) CN104127880A (es)
AR (1) AR076147A1 (es)
AU (1) AU2010227552B2 (es)
BR (1) BRPI1013588A2 (es)
CA (1) CA2756853A1 (es)
CL (1) CL2011002387A1 (es)
CO (1) CO6361953A2 (es)
DO (1) DOP2011000288A (es)
EA (1) EA021146B1 (es)
IL (1) IL215200A0 (es)
MA (1) MA33221B1 (es)
MX (1) MX2011010151A (es)
NZ (1) NZ595344A (es)
PE (1) PE20120514A1 (es)
SG (1) SG174497A1 (es)
TW (1) TW201100104A (es)
UA (1) UA98911C2 (es)
UY (1) UY32514A (es)
WO (1) WO2010108937A2 (es)
ZA (1) ZA201107022B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2411054A2 (en) * 2009-03-27 2012-02-01 Glaxo Group Limited Drug fusions and conjugates
MX2012003939A (es) * 2009-09-30 2012-07-30 Glaxo Group Ltd Fusiones y conjugados de farmaco.
BR112012029280A2 (pt) * 2010-05-20 2016-11-29 Glaxo Group Ltd variante de domínio variável único de imunoglobulina antialbumina sérica, imunoglobulina anti-sa, ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, uso de uma variante, ligando multiespecífico ou proteína de fusão
EP2579897A1 (en) 2010-06-08 2013-04-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2012136790A1 (en) * 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
HUE047238T2 (hu) * 2011-06-23 2020-04-28 Ablynx Nv Szérumalbuminhoz kötõdõ fehérjék
EP2723769B2 (en) 2011-06-23 2022-06-15 Ablynx NV Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CN102949731A (zh) * 2011-09-16 2013-03-06 西藏海思科药业集团股份有限公司 与glp-2受体特异性结合的药物融合体
CN102949730A (zh) * 2011-09-16 2013-03-06 西藏海思科药业集团股份有限公司 特异结合glp-1受体的药物融合体
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
CN102827277B (zh) * 2012-04-26 2014-12-10 拜明(苏州)生物技术有限公司 抗人血清白蛋白单链抗体及其碳端连接多肽药物的方法
CN102875675B (zh) * 2012-04-26 2015-05-27 拜明(苏州)生物技术有限公司 抗人血清白蛋白单链抗体及其氮端连接多肽药物的方法
RU2015128651A (ru) * 2013-01-31 2017-03-06 Глаксо Груп Лимитед Способ продуцирования белка
BR112016016578A2 (pt) 2014-01-20 2017-10-03 Hanmi Pharm Ind Co Ltd Insulina de ação prolongada e uso daanálogo de insulina, polinucleotídeo, vetor de expressão, transformante, insulina de ação prolongada bem como seu método de preparação e formulação da mesma, conjugado, e uso do mesmo mesma
US10077319B2 (en) * 2014-02-21 2018-09-18 Medimmune, Llc Anti-PCSK9-GLP-1 fusions and methods for use
HUE050007T2 (hu) 2014-05-16 2020-11-30 Ablynx Nv Immunglobulin variábilis domének
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
AR101844A1 (es) 2014-09-12 2017-01-18 Genentech Inc Anticuerpos y conjugados modificados genéticamente con cisteína
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
CA3024500A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding relaxin
EP3517544A4 (en) 2016-09-23 2020-06-03 Hanmi Pharm. Co., Ltd. INSULIN ANALOG HAVING REDUCED INSULIN RECEPTOR BINDING FORCE AND USE THEREOF
CN107281471A (zh) * 2017-06-26 2017-10-24 中国药科大学 一种改构的胰高血糖素样肽－1及其修饰物的应用
EP3604328A4 (en) 2017-03-23 2021-01-06 Hanmi Pharm. Co., Ltd. REDUCED INSULIN ANALOGUE COMPLEX FOR INSULIN RECEPTOR AND ITS USE
TWI744579B (zh) 2017-12-21 2021-11-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI767095B (zh) 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
US11753455B2 (en) 2018-06-21 2023-09-12 Novo Nordisk A/S Compounds for treatment of obesity
CN111234015B (zh) * 2020-02-12 2021-04-06 康维众和(中山)生物药业有限公司 用于延长药物半衰期的抗体、其融合蛋白和应用
CN115485292A (zh) * 2020-03-12 2022-12-16 鄂斯尔美塔根公司 新的双特异性蛋白及其用途
WO2022015039A1 (ko) * 2020-07-14 2022-01-20 (주)지아이이노베이션 글루카곤-유사 펩타이드-1 및 글루카곤-유사 펩타이드-2를 포함하는 융합 단백질 및 이의 용도
WO2024141054A1 (zh) * 2022-12-30 2024-07-04 苏州康宁杰瑞生物科技有限公司 包含融合蛋白的药物组合物及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
JPH04504246A (ja) 1989-03-20 1992-07-30 ザ・ジェネラル・ホスピタル・コーポレーション インシュリン刺激ホルモン
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
DK36492D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
ES2359031T3 (es) 1996-08-08 2011-05-17 Amylin Pharmaceuticals, Inc. Composición farmacéutica que comprende un péptido de exendina-4.
DE69838521T2 (de) 1997-07-07 2008-05-21 Medical Research Council Methode zur Erhöhung der Konzentration von Nucleinsäuremolekülen
DK1019077T4 (da) 1997-08-08 2011-03-07 Amylin Pharmaceuticals Inc Hidtil ukendte exendinagonistforbindelser
ATE381939T1 (de) 1997-11-14 2008-01-15 Amylin Pharmaceuticals Inc Neuartige exendin agonisten
DK1032587T4 (da) 1997-11-14 2013-04-08 Amylin Pharmaceuticals Llc Hidtil ukendte exendinagonist-forbindelser
JP4677095B2 (ja) 1998-02-13 2011-04-27 アミリン・ファーマシューティカルズ，インコーポレイテッド エキセンジンおよびｇｌｐ−１の変力および利尿効果
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
CZ306180B6 (cs) 2000-12-07 2016-09-14 Eli Lilly And Company GLP-1 fúzní proteiny
US20030119734A1 (en) 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
BRPI0414539B8 (pt) 2003-09-19 2021-05-25 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
EA012622B1 (ru) * 2004-06-01 2009-10-30 Домэнтис Лимитед Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
WO2005118786A2 (en) 2004-06-03 2005-12-15 Compugen Ltd. Splice variants of peptide yy, neuropeptide y, pancreatic peptide y and amylin, and uses thereof
CN101128487B (zh) * 2004-12-02 2012-10-10 杜门蒂斯有限公司 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA2718480A1 (en) * 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates
NZ595242A (en) * 2009-02-19 2013-11-29 Glaxo Group Ltd Improved anti-serum albumin binding variants
CN102405232B (zh) * 2009-02-19 2015-08-19 葛兰素集团有限公司 改良的抗血清清蛋白结合变体
EP2411054A2 (en) * 2009-03-27 2012-02-01 Glaxo Group Limited Drug fusions and conjugates
MX2012003939A (es) * 2009-09-30 2012-07-30 Glaxo Group Ltd Fusiones y conjugados de farmaco.

Also Published As

Publication number Publication date
CA2756853A1 (en) 2010-09-30
AU2010227552A1 (en) 2011-11-03
EA201190184A1 (ru) 2012-05-30
CL2011002387A1 (es) 2012-07-20
AR076147A1 (es) 2011-05-18
CN102481373A (zh) 2012-05-30
NZ595344A (en) 2013-09-27
JP2012521971A (ja) 2012-09-20
WO2010108937A2 (en) 2010-09-30
UY32514A (es) 2010-10-29
CN104127880A (zh) 2014-11-05
US8779103B2 (en) 2014-07-15
EA021146B1 (ru) 2015-04-30
IL215200A0 (en) 2011-12-29
MA33221B1 (fr) 2012-04-02
KR20110137819A (ko) 2011-12-23
BRPI1013588A2 (pt) 2016-04-19
WO2010108937A3 (en) 2010-11-25
PE20120514A1 (es) 2012-05-14
US20120100141A1 (en) 2012-04-26
ZA201107022B (en) 2013-03-27
CO6361953A2 (es) 2012-01-20
EP2411054A2 (en) 2012-02-01
AU2010227552B2 (en) 2015-02-26
UA98911C2 (uk) 2012-06-25
US20140193407A1 (en) 2014-07-10
TW201100104A (en) 2011-01-01
SG174497A1 (en) 2011-10-28
MX2011010151A (es) 2011-12-14

Similar Documents

Publication Publication Date Title
DOP2011000288A (es) Fusiones y conjugados de farmaco
DK2437790T3 (da) Konjugeringsfremgangsmåder
BRPI1013246A2 (pt) derivados de benzofuralina
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
BRPI1012770A2 (pt) derivados de tiofeno
BRPI1008749A2 (pt) Derivados de benzodiazepina
UY3955Q (es) Carrocería
BR112012015868A2 (pt) derivados de imidazolidinadiona
BRPI1013844A2 (pt) derivados de piridina-isoxazol
BR112012000763A2 (pt) derivados de piridin-4-ila
DK2318390T3 (da) Pyrrolforbindelser
ECSP12011999A (es) Derivados benzamida sustituidos
BRPI1016117A8 (pt) derivados de isoxazol-isoxazol e isoxazol-isotiazol.
DK2397480T3 (da) Diazepindionderivat
BR112012010242A2 (pt) derivados de heteroarilpiperidina e heteroarilpiperazina
AT507924A3 (de) Gleitelement
BRPI1014454A2 (pt) derivados de isoxazol-pirazol
DK2387580T3 (da) Deoxyactagardinderivater
BR112012016923A2 (pt) Derivados de pirazol
BR112012005503A2 (pt) derivados de isoxazolidina
BR112012002810A2 (pt) derivados de n1-acil-5-fluoropirimidinona
FR2947857B1 (fr) Agencement de deshuileur
BR112012014770A2 (pt) derivados de etinila
BRPI0919791A2 (pt) derivados de alternan
BR112012014459A2 (pt) derivados de pirrolidina.